Research
Hormonal
Subclinical hypothyroidism (SHypo) is more prevalent in patients with Type 2 Diabetes (T2D) than in the general population and is associated with an increased risk of diabetic microvascular complications.
If you have Type 2 Diabetes, you are nearly twice as likely to have subclinical hypothyroidism compared to someone without diabetes. This condition is linked to a higher risk of eye, kidney, and nerve complications. Regular thyroid screening is part of comprehensive diabetes care.
GoodSupportsHIGH confidence
A meta-analysis on 36 articles confirmed a higher pooled prevalence of SHypo in patients with T2D when compared with healthy controls (1.93-fold increased risk...)
Why this rating
Based on a meta-analysis of 36 articles and large longitudinal studies.
Source
Thyroid Dysfunction and Diabetes Mellitus: Two Closely Associated Disorders
Bernadette Biondi et al. · Endocrine Reviews · 2019
DOI 10.1210/er.2018-00163
narrative_reviewCited 569×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Autoimmune thyroid disease (AITD) is significantly more prevalent in patients with Type 1 Diabetes (T1D) than in the general population, sharing common genetic susceptibility factors.Strong
- Untreated thyroid dysfunction (both hyper- and hypothyroidism) impairs metabolic control in diabetic patients, exacerbating glycemic instability and increasing the risk of microvascular complications.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →